1.联合培美曲塞和卡铂一线治疗晚期或转移性非鳞非小细胞肺癌 2.单药二线治疗晚期食管鳞癌 卡瑞利珠单抗(Camrelizumab)是我国恒瑞医药自主研发的PD-1单抗隆抗体,且具有自主知识产权。在2019年早已在中国上市,此前有两种获批适应症:复发/难治性霍奇金淋巴瘤和晚期肝细胞癌。 截止目前,算上本次斩获的2个新适应症,...
we will summarize the main clinical trial data of PD1/PD-L1 inhibitors in the treatment of ccRCC, including the trial results of drugs such as Nivolumab and Pembrolizumab. We will explore
In one aspect, disclosed herein are PD-1 chimeric peptides for stimulating an immune response to a PD-1 protein comprising one or more PD-1 B cell epitopes, a T helper (Th) epitope (for example, a measles virus fusion protein peptide such as SEQ ID NO: 6), and a linker (such as,...
anti-PD1 drugs were used as second-line therapy in thirteen studies,[11,12,14,15,22–25,27,29–32], first-line therapy in three studies [26,33,34] and a combination of both in two studies. [13,28] Different PD1/PDL1 inhibitors were administered. Show abstract Treatment of Recurrent ...
Checkmate032纳入的是既往标准化疗失败的SCLC,比较的仍然是联合用药与单纯纳武利尤单抗治疗的疗效。结果显示, 纳武利尤单抗单药ORR为11%,O+伊匹联用ORR为23%,双免疫的疗效翻倍。按PDL1表达分层,未能看出疗效的差异。同样,双免疫治疗的中位OS也优于纳武利尤单抗单药,为7.8 vs 4.1个月。
Checkmate032纳入的是既往标准化疗失败的SCLC,比较的仍然是联合用药与单纯纳武利尤单抗治疗的疗效。结果显示, 纳武利尤单抗单药ORR为11%,O+伊匹联用ORR为23%,双免疫的疗效翻倍。按PDL1表达分层,未能看出疗效的差异。同样,双免疫治疗的...
2B). Interestingly, the combination treatment did induce more T cell activation related genes in Hepa 1–6 tumors (Fig. 2C), suggesting that the function of T cells could be enhanced. We wondered if YIV-906 had an impact on PD1 and PDL1 protein expression leading to stronger T cell ...
Hoos, A. Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations.Nat Rev Drug Discov15, 235–247 (2016). https://doi.org/10.1038/nrd.2015.35 Download citation Published11 March 2016 Issue DateApril 2016 DOIhttps://doi.org/10.1038/nrd.2015.35 ...